MAOB and hearing loss disorder: The DA neurotransmission enhancer rasagiline (a monoamine oxidase type B inhibitor) has been approved as an otoprotectant, showing that DA release from lateral olivocochlear fibers exert a protective action against excitotoxicity, a pathological factor in the aminoglycoside-induced sensorineural hearing loss [50].